+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

V

Actively Recruiting

This research evaluates the effectiveness of a personalized, stepped, multidisciplinary intervention delivered through a virtual multimodal rehabilitation hub for adults undergoing colorectal cancer surgery. The study aims to reduce postoperative complications within 30 days after surgery compared to usual care. Secondary goals include assessing quality of life, recovery quality, days spent at home after surgery, cost-effectiveness, and implementation metrics. Participants are randomly assigned to either the virtual multimodal hub intervention or usual care. The intervention includes tailored exercise, nutritional, psychological, nursing support, and peer support groups before and after surgery. The frequency and type of support are individualized and delivered virtually, with tablets provided if needed. The intervention may continue up to 12 months post-surgery, while the control group receives usual care without additional virtual support. Participants are screened and consented before surgery, followed by baseline assessments and randomization. Throughout the study, researchers monitor postoperative complications, quality of life, recovery, days at home, resource use, and implementation outcomes at multiple time points up to 12 months after surgery. Safety is overseen by an independent committee to ensure participant well-being during the approximately 60-month study period.

Age: 18Years +All GendersPhase Not Applicable
31 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether expanding the use of finger-stick point-of-care testing for hepatitis C virus HCV can improve diagnosis and treatment rates among people at risk for HCV infection. This observational cohort study is conducted by the Kirby Institute and aims to support Australias goal of eliminating HCV by 2030 amid challenges such as declining treatment uptake and impacts from COVID-19. The study focuses on populations with risk factors, including those attending drug treatment clinics, needle and syringe programs, prisons, and other community services. Participants will attend a single visit where they will receive point-of-care HCV antibody testing, providing results within 1 to 20 minutes. If antibody positive, a further point-of-care HCV RNA test will be done to detect active infection. Those with previous HCV infection or treatment will be tested directly with the HCV RNA test. The study does not provide treatment, but participants testing positive for HCV RNA will be connected to standard care pathways for treatment initiation and further clinical evaluation. During the visit, participants will also complete a self-administered survey. Researchers will link survey responses to administrative data to assess long-term health outcomes and the impact of testing scale-up. The primary outcome is the proportion of participants who start HCV treatment within 12 weeks after testing positive. Secondary outcomes include treatment uptake timing, completion rates, cure rates, and cost-effectiveness of testing strategies. Participation involves only one visit, but follow-up data will be collected through linkage to health records over time.

Age: 18Years +All Genders
69 locations